Literature DB >> 19597799

Does diabetes therapy influence the risk of cancer?

U Smith, E A M Gale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19597799     DOI： 10.1007/s00125-009-1441-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  51 in total

Review 1.  The IGF-1 receptor in cancer biology.

Authors:  Renato Baserga; Francesca Peruzzi; Krysztof Reiss
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

2.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

3.  Inhaled insulin: gone with the wind?

Authors:  C Mathieu; E A M Gale
Journal:  Diabetologia       Date:  2008-01       Impact factor: 10.122

4.  Mortality in people with type 2 diabetes in the UK.

Authors:  H E Mulnier; H E Seaman; V S Raleigh; S S Soedamah-Muthu; H M Colhoun; R A Lawrenson
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

5.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

6.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis.

Authors:  Susanna C Larsson; Nicola Orsini; Alicja Wolk
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

8.  Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor.

Authors:  L J Slieker; G S Brooke; R D DiMarchi; D B Flora; L K Green; J A Hoffmann; H B Long; L Fan; J E Shields; K L Sundell; P L Surface; R E Chance
Journal:  Diabetologia       Date:  1997-07       Impact factor: 10.122

9.  Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay.

Authors:  A Agin; N Jeandidier; F Gasser; D Grucker; R Sapin
Journal:  Diabetes Metab       Date:  2007-03-13       Impact factor: 6.041

10.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122
View more
  115 in total

Review 1.  Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies.

Authors:  Ying Jiang; Qiwen Ben; Hong Shen; Weiqi Lu; Yong Zhang; Jun Zhu
Journal:  Eur J Epidemiol       Date:  2011-09-22       Impact factor: 8.082

2.  Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?

Authors:  Andrew J Krentz; Alan J Sinclair
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

3.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

4.  New expectations from the well-known medicinal properties of Arctium lappa.

Authors:  C Miele; F Beguinot
Journal:  Diabetologia       Date:  2012-02-23       Impact factor: 10.122

5.  Cancer and diabetes: are we ready for prime time?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2010-06-13       Impact factor: 10.122

Review 6.  Insulin therapy and cancer risk in diabetes mellitus.

Authors:  Julia Platts
Journal:  Clin Med (Lond)       Date:  2010-10       Impact factor: 2.659

7.  [Panorama of currently available treatments for patients with type 2 diabetes. The ADA/EASD treatment algorithm. Safety and tolerability].

Authors:  Sara Artola Menéndez
Journal:  Aten Primaria       Date:  2010-09       Impact factor: 1.137

Review 8.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  [Insulin therapy of diabetes].

Authors:  Monika Lechleitner; Michael Roden; Raimund Weitgasser; Bernhard Ludvik; Peter Fasching; Friedrich Hoppichler; Alexandra Kautzky-Willer; Guntram Schernthaner; Rudolf Prager; Thomas C Wascher
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

10.  No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.

Authors:  A Dejgaard; H Lynggaard; J Råstam; M Krogsgaard Thomsen
Journal:  Diabetologia       Date:  2009-10-17       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.